These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24708931)

  • 1. Utility of the reverse wire technique in multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation.
    Maekawa Y; Jinzaki M; Anzai A; Matsumura K; Tsuruta H; Kawakami T; Hayashida K; Yuasa S; Murata M; Suzuki M; Kuribayashi S; Fukuda K
    Int J Cardiol; 2014 May; 173(3):e33-4. PubMed ID: 24708931
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful second attempt multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation for an octogenarian with hypertrophic obstructive cardiomyopathy.
    Maekawa Y; Jinzaki M; Anzai A; Tsuruta H; Matsumura K; Yamada Y; Tabei R; Kawakami T; Hayashida K; Yuasa S; Murata M; Suzuki M; Kuribayashi S; Fukuda K
    Int J Cardiol; 2014 Oct; 176(3):e131-2. PubMed ID: 25150473
    [No Abstract]   [Full Text] [Related]  

  • 3. Improved renal function in a patient with hypertrophic obstructive cardiomyopathy after multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation.
    Maekawa Y; Jinzaki M; Tsuruta H; Akita K; Yamada Y; Kawakami T; Hayashida K; Yuasa S; Murata M; Fukuda K
    Int J Cardiol; 2015 Feb; 181():349-50. PubMed ID: 25555276
    [No Abstract]   [Full Text] [Related]  

  • 4. Multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation in a Noonan syndrome patient with hypertrophic obstructive cardiomyopathy.
    Maekawa Y; Jinzaki M; Tsuruta H; Yamada Y; Kishino Y; Kawakami T; Hayashida K; Yuasa S; Murata M; Kawamura A; Sano M; Kuribayashi S; Fukuda K
    Int J Cardiol; 2014; 172(1):e79-81. PubMed ID: 24411913
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy.
    Mitsutake R; Miura S; Sako H; Nishikawa H; Saku K
    Int J Cardiol; 2008 Sep; 129(2):e61-3. PubMed ID: 17888532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful percutaneous transluminal septal myocardial ablation through a right superior septal artery for a patient with hypertrophic obstructive cardiomyopathy.
    Kurita T; Tsuchikane E; Tanaka N; Suzuki T
    Cardiovasc Interv Ther; 2015 Oct; 30(4):377-81. PubMed ID: 25502014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparable effects of percutaneous transluminal septal myocardial ablation and subaortic ventriculotomy in treating patients with hypertrophic obstructive cardiomyopathy, an echocardiography follow-up study].
    Li J; Liu YL; He Q; Qiao SB; Feng W; Lü XZ; Zhu ZH; Ling Y; Wang JP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Aug; 34(8):695-8. PubMed ID: 17081391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echocardiography-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Hsieh TC; Patel K
    Anesth Analg; 2011 Jul; 113(1):44-6. PubMed ID: 21519056
    [No Abstract]   [Full Text] [Related]  

  • 9. "Moving left ventricular obstruction" due to stress cardiomyopathy in a patient with hypertrophic obstructive cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.
    Akita K; Maekawa Y; Tsuruta H; Okuda S; Yanagisawa R; Kageyama T; Kawakami T; Kanazawa H; Hayashida K; Yuasa S; Murata M; Jinzaki M; Fukuda K
    Int J Cardiol; 2016 Jan; 202():194-5. PubMed ID: 26397409
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal branch selection in alcohol septal ablation.
    Toutouzas K; Karanasos A; Anastasakis A; Vavuranakis M; Seggewiss H; Stefanadis C; Rigopoulos A
    Int J Cardiol; 2011 Feb; 147(1):143-4. PubMed ID: 19910065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midterm outcomes of percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy refractory to medication.
    Chen SL; Ye F; Xu ZL; Lin S; Duan BX; Dai ZL; Shan SJ; Zhang JJ
    Chin Med J (Engl); 2006 Jul; 119(13):1121-4. PubMed ID: 16834933
    [No Abstract]   [Full Text] [Related]  

  • 12. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Senaratne V; Sathanandan S; Ekanayake RA
    Ceylon Med J; 2003 Sep; 48(3):92-3. PubMed ID: 14735809
    [No Abstract]   [Full Text] [Related]  

  • 13. Percutaneous transluminal septal myocardial ablation performed via the right coronary artery rather than the left anterior descending artery for the treatment of hypertrophic obstructive cardiomyopathy.
    Takagi K; Mukawa H; Morishima I; Uesugi M; Okumura Y; Tsuboi H; Sone T
    Int J Cardiol; 2013 Jan; 162(3):e51-2. PubMed ID: 22981456
    [No Abstract]   [Full Text] [Related]  

  • 14. Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Transcoronary and Endocardial Approach.
    Aksu T; Guler T; Yalin K; Golcuk SE; Ozcan K
    Am J Med Sci; 2016 Nov; 352(5):466-471. PubMed ID: 27865293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-dimensional flow magnetic resonance imaging reveals the reduction in turbulent kinetic energy after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Iwata K; Matsuda J; Imori Y; Sekine T; Takano H
    Eur Heart J; 2020 Apr; 41(14):1454. PubMed ID: 31504420
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.
    Zeng Z; Wang F; Dou X; Zhang S; Pu J
    Int J Cardiol; 2006 Sep; 112(1):80-4. PubMed ID: 16507323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in patients with prior coronary revascularization.
    Khouzam RN; Naidu SS
    J Invasive Cardiol; 2010 Dec; 22(12):E220-4. PubMed ID: 21127375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial perfusion after percutaneous transluminal septal myocardial ablation as assessed by myocardial contrast echocardiography in patients with hypertrophic obstructive cardiomyopathy.
    Pedone C; Biagini E; Galema TW; Vletter WB; ten Cate FJ
    J Am Soc Echocardiogr; 2006 Aug; 19(8):982-6. PubMed ID: 16880092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI of cardiac morphology and function after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Amano Y; Takayama M; Amano M; Kumazaki T
    AJR Am J Roentgenol; 2004 Feb; 182(2):523-7. PubMed ID: 14736694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4D Computed Tomography Visualization of Effective Septal Reduction After Alcohol Septal Ablation for Fatal Hypertrophic Obstructive Cardiomyopathy.
    Akita K; Kaneko Y; Sato R; Iguchi K; Suwa K; Maekawa Y
    Circ J; 2022 Mar; 86(4):725. PubMed ID: 34853278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.